At the beginning of August, a press roundtable on the specialist field of oncology was held in Zurich. Insight was provided into “targeted therapy” in breast carcinoma, acute lymphoblastic leukemia (ALL), and non-small cell lung cancer (NSCLC), and two new approvals in the Swiss healthcare market and one indication extension were discussed.
Dieser Inhalt ist nur für Benutzer der Gruppe: zugänglich
Jetzt beitreten
Jetzt beitreten
Already a member? Log in here
